Home > Healthcare > Medical Devices > Diagnostic Devices > Rabies Diagnostics Market

Rabies Diagnostics Market - By Test Type (Fluorescent Antibody, Immunohistochemical, Amplification, Serology), Technology (Elisa, Chromatography, PCR), Sample Type (Brain Tissue, Saliva, Cerebrospinal Fluid, Blood) End-Use – Global Forecast 2024 – 2032

  • Report ID: GMI10186
  • Published Date: Jul 2024
  • Report Format: PDF

Rabies Diagnostics Market Size

Rabies Diagnostics Market size was valued at around USD 1.8 billion in 2023 and is estimated to grow at 4.7% CAGR from 2024 to 2032. The rising cases of animal bites, coupled with favorable government policies, are significantly driving the growth of the market.

Rabies Diagnostics Market

An increase in animal bite incidents, particularly from stray dogs, increases the need for animal diagnostics and heightened the need for effective and rapid diagnostic solutions to prevent the spread of rabies. Governments worldwide are implementing policies and programs to address this issue. For instance, World Health Organization (WHO), in collaboration with multiples partners, launched the "United Against Rabies" initiative in 2020, which aims to accelerate efforts to eradicate rabies through widespread dog vaccination and enhanced human treatment protocols.

Additionally, regulatory support for the development and deployment of advanced diagnostic tools is fostering market growth. These combined efforts not only aim to reduce rabies incidence but also ensure timely diagnosis and treatment, thereby propelling the demand for rabies diagnostic market.

Rabies diagnostics refer to the methods and techniques used to detect and confirm the presence of rabies virus in animals and humans. These diagnostics are essential for the accurate identification of rabies infection, which is critical for timely treatment and prevention measures.

Rabies Diagnostics Market Trends

Recent technological advancements in rabies diagnostics are significantly driving market growth. The combination of AI, point-of-care testing, and advanced molecular techniques represents a significant leap forward in the fight against rabies.

  • AI-driven tools can quickly analyze and interpret complex data from various diagnostic tests, reducing the likelihood of human error and ensuring rapid, precise detection of the rabies virus.
  • Also, the development of point-of-care testing devices which allow for immediate, on-site diagnosis of rabies are gaining momentum. These portable diagnostic tools are particularly valuable in remote or resource-limited settings, where access to traditional laboratory facilities is often limited.
  • Additionally, innovations in molecular diagnostics, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), have greatly improved the sensitivity and specificity of rabies detection, further enhancing the ability to accurately diagnose the disease at earlier stages?.
  • These technological advancements are not only improving diagnostic capabilities but also fostering market growth by meeting the rising demand for efficient and reliable rabies diagnostics solutions.

Rabies Diagnostics Market Analysis

Rabies Diagnostics Market, By Test Type, 2021 – 2032 (USD Billion)

Based on test type, the market is categorized into fluorescent antibody test (FAT), immunohistochemical test, amplification methods, histologic examination, and serology tests. The fluorescent antibody test (FAT) segment dominated the market, generating approximately USD 503.1 million revenue in 2023.

  • FAT has been a well-established and widely used method for rabies diagnosis for several decades. Its reliability, accuracy, and long history of use make it a trusted diagnostic tool among veterinarians, public health officials, and laboratory professionals, propelling the market growth.
  • Additionally, FAT provides relatively quick results compared to some other diagnostic methods. It typically takes only a few hours to perform the test and interpret the results, allowing for prompt diagnosis and timely implementation of control measures, hence increases its demand in the market.

Based on technology, the rabies diagnostics market is categorized into ELISA, chromatography, PCR, and other techniques. The ELISA segment is anticipated to witness highest growth to reach USD 911.3 million by 2032.

  • ELISA assays are known for their high sensitivity and specificity in detecting antibodies or antigens related to the rabies virus. This ensures accurate diagnosis, which is crucial for effective disease management and control.
  • Additionally, ELISA assays are generally cost-effective compared to some other diagnostic methods, such as PCR technology. They require less specialized equipment and reagents, making them suitable for resource-limited settings and high-throughput testing scenarios, contributing to its segmental growth.  

Based on sample type, the rabies diagnostics market is categorized into brain tissue, saliva, cerebrospinal fluid (CSF), blood (serum) and other sample types. The brain tissue segment dominated the market, with a revenue share of around 27.8% in 2023.

  • Brain tissue is considered the gold standard for rabies diagnosis as it provides the most accurate and definitive results. Tests like the direct fluorescent antibody test (FAT) and immunohistochemistry (IHC) are performed on brain tissue and are highly sensitive and specific for detecting the rabies virus?.
  • Additionally, brain tissue samples typically contain a higher concentration of the rabies virus compared to other sample types. This high viral load increases the likelihood of detecting the virus, making diagnostic tests on brain tissue more effective and reliable.


Rabies Diagnostics Market, by End-use (2023)

Based on end-use, the rabies diagnostics market is categorized into hospitals and clinics, and diagnostic laboratories. The hospitals and clinics segment dominated the market, with a revenue share of around 54.4% in 2023.

  • Hospitals are the primary facilities for diagnosing and treating human cases of rabies. They play a crucial role in diagnosing and managing cases where individuals have been exposed to the virus.
  • Additionally, many hospitals have laboratories equipped to perform a range of diagnostic tests, including rapid diagnostic tests, immunohistochemical tests, and molecular assays like PCR. Hospitals can quickly confirm or rule out rabies in suspected cases, facilitating prompt treatment decisions, hence contributing to the segment growth.    


North America Rabies Diagnostics Market, 2021 – 2032 (USD Million)

North America rabies diagnostics market accounted for USD 765.8 million revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.

  • The prevalence of rabies in North America drives the demand for diagnostics. Rabies remains a concern in wildlife populations, particularly in certain regions, leading to a need for accurate and efficient diagnostic tools.
  • Additionally, investments in research and development (R&D) drive innovation in rabies diagnostics, leading to the development of new diagnostic assays, kits, and technologies. Collaboration between academia, industry, and government institutions fosters the development of novel diagnostic tools and contributes to market growth.

U.S. rabies diagnostics market held a dominant position with a share of 93% in 2023 within the North American region.  

  • The market is driven by the need for early detection and control of rabies. Key factors contributing to market growth include increasing awareness about rabies prevention, advancements in diagnostic technologies, and government initiatives for rabies control.
  • The rising incidence of rabies in wildlife and pets further fuels the demand for effective diagnostic solutions in the country.

Germany rabies diagnostics market is expected to grow significantly during the forecast period.

  • The availability of well-equipped veterinary clinics, laboratories, and diagnostic facilities in the country impacts the demand for veterinary rapid tests, in turn propelling the market.
  • Additionally, economic conditions, healthcare spending, reimbursement policies, and insurance coverage influence the adoption of diagnostic tests for rabies in the country.

China rabies diagnostics market is anticipated to witness a high growth rate from 2024-2032, due to several factors.

  • The increasing prevalence of neglected tropical diseases (NTDs) in China is a significant public health concern. Many neglected tropical diseases share overlapping geographic distributions with rabies, particularly in rural and impoverished areas. This overlap increases the likelihood of co-infections or misdiagnosis, necessitating comprehensive diagnostic testing, including rabies.
  • Access to healthcare services and diagnostic facilities in certain rural areas of China is limited. This results in delays in diagnosis and treatment, allowing NTDs to spread unchecked, which increases the need for rapid diagnostics. This in turn drives the market growth.

Rabies Diagnostics Market Share

The global market is characterized by a competitive landscape driven by advancements in diagnostic technologies, increasing investment in research and development, and a focus on early disease detection. The development and launch of novel products with improved efficiency and cost-effectiveness are key market strategies for rabies diagnostics product manufacturers, driving competition and innovation in the industry. The market is further intensified by the presence of regional players who cater to local demands and regulatory requirements. Collaborations between veterinary organizations, government bodies, and diagnostic companies are pivotal in promoting widespread adoption of rabies diagnostics, thereby driving market growth.

Rabies Diagnostics Market Companies

Some of the eminent market participants operating in the rabies diagnostics industry include:

  • Abbexa Ltd
  • Aviva Systems Biology Corporation
  • Bio-Rad Laboratories, Inc.
  • Creative Diagnostics
  • Demeditec Diagnostics GmbH
  • Merck KGaA
  • MyBioSource, Inc.
  • Norgen Biotek Corp.
  • Thermo Fisher Scientific Inc.

Rabies Diagnostics Industry News:

  • In March 2024, Merck Animal Health, a division of Merck & Co., Inc., announced a continued commitment to rabies elimination through a donation of NOBIVAC rabies vaccines to the Mission Rabies program, a charity initiative of the Worldwide Veterinary Service (WVS). This commitment aided the company’s reputation in the market and positioned it as one of the leading players in the market.

Rabies diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

  • Fluorescent antibody test (FAT)
  • Immunohistochemical test
  • Amplification methods
  • Histologic examination
  • Serology tests

Market, By Technology

  • Chromatography
  • PCR
  • Other techniques

Market, By Sample Type

  • Brain tissue
  • Saliva
  • Cerebrospinal fluid (CSF)
  • Blood (Serum)
  • Other sample types

Market, By End-use

  • Hospitals and clinics
  • Diagnostic laboratories

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Rabies diagnostics industry size was USD 1.8 billion in 2023 and is projected to expand at 4.7% CAGR from 2024 to 2032, due to the rising cases of animal bites, coupled with favorable government policies.

The fluorescent antibody test (FAT) segment in the rabies diagnostics industry accounted for USD 503.1 million in 2023 and is estimated to grow at significant CAGR from 2024 to 2032, owing to its reliability, accuracy, and long history of use.

The ELISA technology segment in the rabies diagnostics industry is projected to record USD 911.3 million by 2032, due to their high sensitivity and specificity in detecting antibodies or antigens related to the rabies virus.

North America rabies diagnostics industry amassed USD 765.8 million in revenue in 2023 and is projected to depict substantial gains from 2024 to 2032, led by the growing prevalence of rabies in the region.

Rabies Diagnostics Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 251
  • Countries covered: 23
  • Pages: 130
 Download Free Sample